• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [16524 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2012     NIHR Horizon Scanning Centre (NIHR HSC) WOUNDCHEK™ Protease status point of care test for chronic wounds
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Argatroban (Exembol®) 100 mg/ml concentrate for solution for infusion
2012     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [DETECTA-T]
2012     Institute for Clinical Evaluative Sciences (ICES) Health outcomes for better information and care (HOBIC): acute care in Ontario
2012     Institute for Clinical Evaluative Sciences (ICES) Ontario stroke evaluation report 2012: prescribing system solutions to improve stroke outcomes
2012     Institute for Clinical Evaluative Sciences (ICES) Hospital care for all: an equity report on differences in household income among patients at Toronto Central Local Health Integration Network (TC LHIN) hospitals, 2008-2010
2012     Health Council of the Netherlands Gezondheidsraad (GR) The mental health of young migrants and their uptake of care
2012     Institute for Clinical Evaluative Sciences (ICES) Seven more years: the impact of smoking, alcohol, diet, physical activity and stress on health and life expectancy in Ontario
2012     Health Council of the Netherlands Gezondheidsraad (GR) New anticoagulants: a well-dosed introduction
2012     Institute for Clinical Evaluative Sciences (ICES) Regional measures of diabetes burden in Ontario
2012     Health Council of the Netherlands Gezondheidsraad (GR) Perspectives on oral health care
2012     Institute for Clinical Evaluative Sciences (ICES) Comparison of primary care models in Ontario by demographics, case mix and emergency department use, 2008/09 to 2009/10
2012     Institute for Clinical Evaluative Sciences (ICES) Payments to Ontario physicians from ministry of health and long-term care sources, 1992/93 to 2009/10
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Lenalidomide (Revlimid®) for the treatment of low /intermediate-1 risk myelodysplastic syndrome with chromosome 5q deletion
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Brentuximab (Adcetris®) for the treatment of relapsed Hodgkin's lymphoma (HL) or relapsed systemic anaplastic large cell lymphoma (sALCL)
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Romidepsin (Istodax®) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) after prior systemic therapy
2012     Technology Assessment at SickKids (TASK) The use of biologic response modifiers in polyarticularcourse juvenile idiopathic arthritis - a systematic review update
2012     Penn Medicine Center for Evidence-based Practice (CEP) Outcomes associated with long-term acute care hospitals
2012     Penn Medicine Center for Evidence-based Practice (CEP) Guidelines for admission to long-term acute care hospitals
2012     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Microbial sealant to reduce surgical site infections following coronary artery bypass graft
2012     Penn Medicine Center for Evidence-based Practice (CEP) Specialized neurocritical care units for traumatic brain injury
2012     Penn Medicine Center for Evidence-based Practice (CEP) Screening tests for aspiration and dysphagia
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous repair of mitral regurgitation with the MitraClip]
2012     Penn Medicine Center for Evidence-based Practice (CEP) Best practices for preventing aspiration pneumonia in hospitalized patients
2012     Penn Medicine Center for Evidence-based Practice (CEP) Guidelines for platelet or plasma transfusion in lumbar puncture patients
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Impact evaluation and environmental analysis
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Ipilimumab (Yervoy®) for the first-line therapy of advanced/metastatic cutaneous melanoma
2012     HAYES, Inc. Afirma® thyroid FNA analysis
2012     Penn Medicine Center for Evidence-based Practice (CEP) CT for acute chest pain
2012     HAYES, Inc. Anaplastic lymphoma kinase (ALK) gene rearrangement testing in non-small cell lung cancer (NSCLC)
2012     Institute for Clinical Evaluative Sciences (ICES) Opening eyes, opening minds: the Ontario burden of mental illness and addictions report
2012     NIHR Health Technology Assessment programme A pragmatic randomised controlled trial to evaluate the cost-effectiveness of a physical activity intervention as a treatment for depression: the treating depression with physical activity (TREAD) trial
2012     Penn Medicine Center for Evidence-based Practice (CEP) Bone morphogenetic proteins and bone marrow aspirate concentrate for tibial fractures and long bone nonunions
2012     HAYES, Inc. Fibrinogen-beta (FGB) c.-455G>A polymorphism testing in cardiovascular disease
2012     NIHR Health Technology Assessment programme Outcomes of social care for adults: developing a preference weighted measure
2012     Penn Medicine Center for Evidence-based Practice (CEP) Comparative effectiveness of devices for detection of respiratory distress in post-operative patients
2012     Penn Medicine Center for Evidence-based Practice (CEP) Hyperthermic intraperitoneal chemotherapy
2012     HAYES, Inc. Cognitive-behavioral therapy for bulimia nervosa
2012     HAYES, Inc. Harmony™ Prenatal Test
2012     Penn Medicine Center for Evidence-based Practice (CEP) Electromagnetically-assisted feeding tube placement
2012     HAYES, Inc. Coronary artery calcium scoring to assess the risk of coronary artery disease in asymptomatic adults
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Bortezomib (Velcade®) as consolidation or maintenance therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma
2012     HAYES, Inc. Mammostrat® for prognosis of breast cancer recurrence
2012     NIHR Horizon Scanning Centre (NIHR HSC) Sebelipase alfa for lysosomal acid lipase deficiency
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2- negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole
2012     HAYES, Inc. Multiple endocrine neoplasia type 2 (MEN2)
2012     HAYES, Inc. Custom total knee arthroplasty
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pertuzumab (Omnitarg/Perjeta®) for the first-line therapy of metastatic HER2 positive breast cancer
2012     HAYES, Inc. Thyroid hormone receptor beta (THRB) gene testing in resistance to thyroid hormone (RTH)
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Rilpivirine (Edurant®)
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Rifaximin (Xifaxanta®)
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Nevirapine (Viramune®)
2012     Health Information and Quality Authority (HIQA) Health technology assessment of a national deep brain stimulation service in Ireland
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Diagnostic agreement of digital whole slide imaging and routine light microscopy
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Vitamin D supplementation in patients with active or latent tuberculosis
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Prosthetic arthroplasty in primary shoulder osteoarthritis
2012     Medical Advisory Secretariat (MAS) Specialized community-based care: an evidence-based analysis
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Intraoperative cortical stimulation in brain tumor surgery
2012     NIHR Health Technology Assessment programme Vemurafenib for the treatment of locally advanced or metastatic BRAF V600E mutation positive malignant melanoma
2012     NIHR Horizon Scanning Centre (NIHR HSC) Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) for mucopolysaccharidosis type IVA – first line
2012     NIHR Horizon Scanning Centre (NIHR HSC) Fostamatinib for rheumatoid arthritis – second line
2012     Institute of Health Economics (IHE) First and second trimester prenatal screening for trisomies 13, 18, and 21 and open neural tube defects
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Timing of umbilical cord clamping for neonatal and maternal outcomes
2012     NIHR Horizon Scanning Centre (NIHR HSC) Thymosin beta-4 for dry eye syndrome
2012     Institute of Health Economics (IHE) Bariatric treatments for adult obesity
2012     The Regional Health Technology Assessment Centre (HTA-centrum) EEG as a diagnostic tool in patients with first episode psychosis
2012     Medical Advisory Secretariat (MAS) Genetic testing for predisposition to dilated cardiomyopathy
2012     NIHR Horizon Scanning Centre (NIHR HSC) Dexamethasone posterior segment drug delivery system (Ozurdex) for diabetic macular oedema– first or second line
2012     Institute of Health Economics (IHE) Insulin pump therapy for type 1 diabetes
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Psychological treatment of dental anxiety among adults
2012     Agenzia nazionale per i servizi sanitari regionali (Agenas) FDG-PET/CT for cancer staging
2012     NIHR Horizon Scanning Centre (NIHR HSC) Ciclosporin A (Cyclokat) for keratoconjunctivitis sicca
2012     NIHR Horizon Scanning Centre (NIHR HSC) Ponatinib for chronic myeloid leukaemia or Ph+ acute lymphoblastic leukaemia
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Botulinum toxin treatment of axillary and palmar hyperhidrosis
2012     Agenzia nazionale per i servizi sanitari regionali (Agenas) New devices for the management of glycaemia in young diabetics
2012     Medical Services Advisory Committee (MSAC) Pathology tests for latent mycobacterial infection
2012     NIHR Horizon Scanning Centre (NIHR HSC) Bitopertin for schizophrenia: primary, persistent negative symptoms; sub-optimally controlled positive symptoms – in combination with antipsychotics
2012     NIHR Horizon Scanning Centre (NIHR HSC) Liposomal cisplatin (Nanoplatin) for advanced non-small cell lung cancer – first line
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Hyperbaric oxygen therapy in the treatment of diabetic foot ulcers and late radiation tissue injuries of the pelvis
2012     NIHR Horizon Scanning Centre (NIHR HSC) BI 201335 for chronic hepatitis C infection
2012     NIHR Horizon Scanning Centre (NIHR HSC) Liposomal cisplatin (Lipoplatin) in combination with gemcitabine for pancreatic cancer – first line
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Eculizumab treatment in paroxysmal nocturnal hemoglobinuria
2012     Medical Services Advisory Committee (MSAC) Testing for HER2 positivity in patients diagnosed with breast cancer to determine eligibility for treatment with trastuzumab
2012     NIHR Horizon Scanning Centre (NIHR HSC) Racecadotril for acute diarrhoea: infants (older than 3 months), children and adults – add on to oral rehydration therapy
2012     NIHR Horizon Scanning Centre (NIHR HSC) Enzalutamide for chemotherapy naive castration-resistant prostate cancer
2012     NIHR Horizon Scanning Centre (NIHR HSC) Peginesatide for anaemia in chronic kidney disease – first and second line
2012     NIHR Horizon Scanning Centre (NIHR HSC) Trametinib in combination with dabrafenib for V600 BRAF positive advanced malignant melanoma – first line
2012     HAYES, Inc. Aquatic therapy for mobility impairment in children
2012     Medical Services Advisory Committee (MSAC) Testing for BRAF mutation in patients with metastatic melanoma for access to (1c) vemurafenib
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Vemurafenib for the 1st –line unresectable stage IIIC or IV melanoma
2012     NIHR Horizon Scanning Centre (NIHR HSC) Vosaroxin in combination with cytarabine for acute myeloid leukamaemia
2012     NIHR Horizon Scanning Centre (NIHR HSC) Carfilzomib (Kryprolis) for multiple myeloma – third line
2012     HAYES, Inc. Extracorporeal membrane oxygenation (ECMO) for out-of-hospital cardiac arrest in adults
2012     Medical Services Advisory Committee (MSAC) Radiofrequency ablation (RFA) for the treatment of varicose veins due to chronic venous insufficiency
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Erlotinib for the 1st -line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations
2012     NIHR Horizon Scanning Centre (NIHR HSC) Vinflunine (Javlor) with capecitabine for advanced breast cancer
2012     NIHR Horizon Scanning Centre (NIHR HSC) Bortezomib (Velcade) in combination with dexamethasone or pegylated liposomal doxorubicin for relapsed multiple myeloma
2012     HAYES, Inc. FlexHD acellular dermis (Musculoskeletal Transplant Foundation) for breast reconstruction
2012     Agenzia nazionale per i servizi sanitari regionali (Agenas) Polylactic-glycolic acid absorbable synthetic suture (Pgla) plus antibacterial: a systematic review
2012     University of York Evidence briefing on adherence to treatment for respiratory diseases